Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
Author:
Funder
MSD, INCA DGOS, ARC
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Link
https://www.nature.com/articles/s41591-022-01821-3.pdf
Reference26 articles.
1. Coley, W. B. II Contribution to the knowledge of sarcoma. Ann. Surg. 14, 199–220 (1891).
2. Tawbi, H. A. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18, 1493–1501 (2017); erratum 18, e711; 19, e8 (2018).
3. Toulmonde, M. et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 4, 93–97 (2018).
4. Italiano, A., Bellera, C. & D’Angelo, S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. J. Hematol. Oncol. 13, 55 (2020).
5. Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
Cited by 124 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis;International Immunopharmacology;2024-10
2. Trends in the use of immunotherapy to treat soft tissue sarcoma;The American Journal of Surgery;2024-10
3. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02
4. Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10/CXCR3 to boost antitumor immunity;Cell Proliferation;2024-09
5. Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3